Dynavax Technologies Corporation (NASDAQ:DVAX) posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.09, Briefing.com reports. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. During the same quarter in the prior year, the company posted ($0.75) earnings per share.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) traded up 2.84% during trading on Friday, hitting $16.30. 2,572,043 shares of the company’s stock were exchanged. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $19.60. The firm’s market capitalization is $892.38 million. The stock’s 50 day moving average is $11.71 and its 200 day moving average is $7.12.

Several equities analysts have issued reports on the stock. Cowen and Company restated an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies Corporation in a research note on Thursday. William Blair reiterated an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Wednesday. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. BidaskClub downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, J P Morgan Chase & Co upgraded shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $6.00 to $27.00 in a research note on Monday, July 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Dynavax Technologies Corporation has an average rating of “Hold” and a consensus target price of $23.34.

ILLEGAL ACTIVITY WARNING: “Dynavax Technologies Corporation (DVAX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://theolympiareport.com/2017/08/12/dynavax-technologies-corporation-dvax-releases-earnings-results-beats-expectations-by-0-09-eps-updated.html.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Earnings History for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.